Suppr超能文献

静脉注射羟考酮快速滴定治疗重度癌痛及口服转换比例。

Rapid Titration With Intravenous Oxycodone for Severe Cancer Pain and Oral Conversion Ratio.

机构信息

Main regional center for pain relief and supportive/palliative care, La Maddalena Cancer Center, Palermo, Italy.

Main regional center for pain relief and supportive/palliative care, La Maddalena Cancer Center, Palermo, Italy.

出版信息

J Pain Symptom Manage. 2022 Dec;64(6):532-536. doi: 10.1016/j.jpainsymman.2022.09.004. Epub 2022 Sep 15.

Abstract

CONTEXT

to assess a dose titration with intravenous oxycodone to achieve rapid pain relief of cancer pain of severe intensity. The second objective was to provide a conversion ratio with the oral route.

METHODS

Cancer patients admitted for severe pain were prospectively assessed. At admission (T0) previous opioid doses were recorded. Edmonton symptom assessment scale (ESAS) was collected from T0 until the conclusion of the observation. Intravenous boluses of oxycodone were given until the initial signs of significant analgesia were detected. The effective dose was multiplied for six and given as intravenous continuous infusion. When the patient was considered stabilized the intravenous daily dose was converted to oral oxycodone using an initial ratio of 1:2. Subsequently, doses of oral oxycodone were changed according to the clinical situation.

RESULTS

Twenty-nine patients were examined. A mean effective bolus dose of oxycodone was 9.5 mg (SD 8.0) allowed to achieve a meaningful pain relief in a mean of 10.4 minutes (SD 3.3). The mean initial and the final infusion doses were 51.0 mg/day (standard deviation 40.9) and 69.7 mg/day ( standard deviation76.6), respectively. A significant change in pain intensity was observed at the different time intervals (P<0.0005). Conversion to oral route occurred after a mean of 2.7 days (standard deviation1.2) of intravenous oxycodone. The final mean conversion ratio was 1:2,12 ( standard deviation0.36).

CONCLUSION

Rapid intravenous oxycodone dose titration resulted in rapid pain relief. The intravenous-oral conversion ratio of 1:2 is reliable. Further studies are necessary to confirm this preliminary observation.

摘要

背景

评估静脉注射羟考酮滴定剂量以实现重度癌痛的快速缓解。第二个目标是提供口服途径的转换比值。

方法

前瞻性评估因严重疼痛入院的癌症患者。入院时(T0)记录了先前的阿片类药物剂量。从 T0 开始收集埃德蒙顿症状评估量表(ESAS),直到观察结束。给予静脉推注羟考酮,直到出现明显镇痛的初始迹象。将有效剂量乘以六,并作为静脉持续输注给予。当患者被认为稳定时,使用初始比值 1:2 将静脉日剂量转换为口服羟考酮。随后,根据临床情况调整口服羟考酮的剂量。

结果

检查了 29 名患者。羟考酮有效推注剂量的平均值为 9.5 毫克(标准差 8.0),平均 10.4 分钟(标准差 3.3)可实现有意义的疼痛缓解。初始和最终输注剂量的平均值分别为 51.0 毫克/天(标准差 40.9)和 69.7 毫克/天(标准差 76.6)。在不同的时间间隔观察到疼痛强度的显著变化(P<0.0005)。静脉注射羟考酮平均 2.7 天后(标准差 1.2)开始口服。最终平均转换比值为 1:2.12(标准差 0.36)。

结论

快速静脉羟考酮滴定剂量可迅速缓解疼痛。1:2 的静脉-口服转换比值是可靠的。需要进一步的研究来证实这一初步观察。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验